Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Figure out How to Track and Anticipate Future Cd Rates - 2Activists guilty over Palestine protest breach
- 3Vote In favor of Your Favored Menial helper Administration
- 44 Jeep Models: Dominating Execution and Flexibility for Each Experience
- 5Step by step instructions to Show Children the Significance of Appropriate Handshaking
- IDF confirms Iranian missile fragments hit near Kirya, multiple cars ablaze in Ramat Gan
- The Most Important Crossroads in Olympic History
- The Craft of Computerized Detox: Individual Trials
- What is a Trump Gold Card? U.S. launches $1 million immigration visas
- Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- The most effective method to Pick A Trade-in vehicle Stage
- Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
- Artemis 2 astronauts are about to see one of the rarest skywatching sights of all — a solar eclipse from beyond the moon
- Defeating An inability to embrace success in Scholarly world: Individual Victories
